Zhang X W, Huang Z Q, Li C C
Department of Pharmacology, Fujian Medical College, Fuzhou, China.
Zhongguo Yao Li Xue Bao. 1994 May;15(3):285-8.
Thevetoside (TS) is one of the cardiac glycosides. A study of antitumor activity was carried out in 6 types of murine tumors in vivo, such as the ascitic tumors H22, EAC, P388, and solid tumors S180, U14, Lewis lung carcinoma, which were treated with i.p. TS 1.5 mg.kg-1.d-1 alone or in combination with chlormethine (Chl) 0.3, 0.5, or 1.0 mg.kg-1.d-1. TS only showed a remarkable inhibition on the growth of 3 types of solid tumors with inhibition rates of 48.7%-56.7%. The effect of the combination therapy was much pronounced than that of independent administration. The life span under combined therapy was increased 82.4% to > 122.1%. For solid tumors, the combined administration gave inhibition rates of 65.6%-72.5%.
黄夹苷(TS)是一种强心苷。对6种小鼠肿瘤进行了体内抗肿瘤活性研究,如腹水瘤H22、EAC、P388,以及实体瘤S180、U14、Lewis肺癌,分别单独腹腔注射TS 1.5 mg·kg-1·d-1,或与苯丁酸氮芥(Chl)0.3、0.5或1.0 mg·kg-1·d-1联合使用。TS仅对3种实体瘤的生长有显著抑制作用,抑制率为48.7%-56.7%。联合治疗的效果比单独给药显著得多。联合治疗下的生存期延长了82.4%至>122.1%。对于实体瘤,联合给药的抑制率为65.6%-72.5%。